DexCom Q3 Revenue Rises 11.2% to $1.344 Billion, Maintains Full-Year Guidance of $5.20B-$5.25B

DexCom Inc. (DXCM) reported third-quarter revenue of $1.344 billion, up 11.2% from $1.209 billion a year earlier, as the continuous glucose monitor maker reiterated full-year revenue guidance of $5.20 billion to $5.25 billion. GAAP earnings came in at $275.1 million, or $0.72 per share, compared with $283.8 million, or $0.70 per share, last year. Adjusted earnings were $275.0 million, or $0.73 per share. The slight year-over-year decline in net income came despite the double-digit sales gain, though per-share earnings rose on a higher share count comparison.